New obesity drug HRS-5817 enters first human safety trial
NCT ID NCT06934408
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new injectable drug called HRS-5817 in healthy adults, some with obesity and some without. The main goal is to check safety and how the body handles the drug, not weight loss. About 92 volunteers will receive either the drug or a placebo to gather initial data.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HRS-5817 injection
What this could lead to
If successful, this could lead to a new injectable medication for weight management in people with obesity or overweight.
What could go wrong
This is a very early Phase 1 trial focused on safety, not weight loss. The drug may cause side effects or fail to show benefit in later studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Second Hospital of Anhui Medical Uniersity
RECRUITINGHefei, Anhui, 230601, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact